PFE-360 Inhibitor

Name: PFE-360 Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5755364
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755364

PFE-360 is a potent and selective inhibitor of LRRK2 kinase (IC50: 2.3nM in vivo). More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

PFE-360, Inhibitor

Full Product Name

PFE-360

Product Gene Name

PFE-360, inhibitor

Product Synonym Names

PF-06685360

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

308.34

Solubility

DMSO: 10.2mg/mL (33.08mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C16H16N6O

SMILES

Cn1cc(cc1C#N)-c1c[nH]c2ncnc(N3CCOCC3)c12

CAS Number

1527475-61-1

Target & IC50

LRRK2 in vivo: ic50 2.3nM

In Vitro

PFE-360 (4mg/kg and 7.5mg/kg, orally, BID, 10-12 weeks) treatment, effectively reduces the LRRK2-pSer935/total LRRK2 ratio. It has no significant adverse effects[1].

Product Categories/Family for PFE-360, inhibitor

Autophagy; LRRK2

Product References and Citations for PFE-360, inhibitor

Marco A.S. Baptista, et al. LRRK2 Kinase Inhibitors of Different Structural Classes Induce Abnormal Accumulation of Lamellar Bodies in Type II Pneumocytes in Non-Human Primates but are Reversible and Without Pulmonary Functional Consequences.
Marco A.S. Baptista, et al. LRRK2 Kinase Inhibitors of Different Structural Classes Induce Abnormal Accumulation of Lamellar Bodies in Type II Pneumocytes in Non-Human Primates but are Reversible and Without Pulmonary Functional Consequences.
Andersen MA, et al. Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-alpha-synuclein is normalized by LRRK2 modulation. Neurobiol Dis. 2018 Aug;116:13-27.
Andersen MA, et al. Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-alpha-synuclein is normalized by LRRK2 modulation. Neurobiol Dis. 2018 Aug;116:13-27.
Andersen MA, et al. PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats. Toxicology. 2018 Feb 15;395:15-22.
Andersen MA, et al. PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats. Toxicology. 2018 Feb 15;395:15-22.

Other Notes

Small volumes of PFE-360, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for PFE-360 purchase

MBS5755364 is an inhibitor targeting PFE-360.